Astellas v. Lupin: Consent Judgment Upholds Mirabegron Patent Rights in Landmark Pharma Case
Was möchten Sie als Nächstes tun?
Wählen Sie Ihren Weg entsprechend Ihren aktuellen Bedürfnissen:
📋 Fallzusammenfassung
| Fallbezeichnung | Astellas Pharma, Inc. gegen Lupin Limited |
| Fallnummer | 1:23-cv-00819 (D. Del.) |
| Gericht | US-Bezirksgericht für den Bezirk Delaware |
| Dauer | July 28, 2023 – Feb 19, 2026 2 years 6 months |
| Ergebnis | Plaintiff Win — Permanent Injunction |
| Streitige Patente | |
| Beschuldigte Produkte | Lupin’s Mirabegron extended-release tablets (25 mg and 50 mg) |
Fallübersicht
Die Parteien
⚖️ Kläger
Global biopharmaceutical company and originator of Myrbetriq® (mirabegron), a blockbuster treatment for overactive bladder approved by the FDA. Astellas holds an extensive patent portfolio protecting the drug’s active compound, extended-release formulation, and manufacturing processes.
🛡️ Beklagter
Major Indian generic pharmaceutical manufacturer with significant U.S. market operations. Lupin filed an Abbreviated New Drug Application (ANDA No. 209488) seeking to market generic Mirabegron extended-release tablets in 25 mg and 50 mg dosages — directly challenging Astellas’s market exclusivity.
Die streitigen Patente
This landmark case involved four U.S. patents forming the core of this dispute. The infringement action arose under the Hatch-Waxman Act framework, triggered by Lupin’s ANDA filing with a Paragraph IV certification.
- • US11707451B2 — Mirabegron extended-release formulation (application US17/114890)
- • US ‘780 Patent — Related ER formulation technology
- • US ‘409 Patent — Related ER formulation technology
- • US ‘189 Patent — Related ER formulation technology
Entwickeln Sie eine ähnliche pharmazeutische Formulierung?
Check if your generic drug might infringe these or related patents before launch.
Das Urteil und die rechtliche Analyse
Ergebnis
The court entered a consent judgment and final order on February 19, 2026. Based on Lupin’s admissions, all four asserted patents (‘780, ‘451, ‘409, and ‘189) were found **valid and enforceable**, and at least one claim of each patent was found **infringed** by the Lupin ANDA products. Lupin (including successors and assigns) is **permanently enjoined** from making, using, selling, offering to sell, importing, or distributing the ANDA products in the United States through the expiration of all four patents, including any patent term extensions, adjustments, pediatric exclusivity periods, or other regulatory exclusivities.
No specific monetary damages were awarded. The complaints across all four coordinated actions were dismissed **without prejudice and without costs** to either party.
Zeitplan des Rechtsstreits und Verfahrensgeschichte
- July 28, 2023: Complaint filed in the U.S. District Court for the District of Delaware (Case No. 1:23-cv-00819).
- This action was part of a broader, coordinated litigation campaign by Astellas involving related civil actions — including Case Nos. 20-1589, 24-940, and 24-1069 — all before the same court.
- February 19, 2026: Consent judgment entered, closing the case after approximately 937 days of litigation. This duration is consistent with typical Hatch-Waxman district court timelines.
Rechtliche Bedeutung
This case reinforces a critical pattern in Hatch-Waxman litigation: **multi-patent assertion strategies materially increase settlement pressure on ANDA filers.** When a branded company constructs a patent estate with overlapping formulation, composition, and method claims — as Astellas has done with Mirabegron — generic challengers face the compounded risk of losing on any single patent, triggering injunctive relief regardless of success on others.
The consent judgment’s explicit extension of the injunction through **all regulatory exclusivities** — including pediatric exclusivity — is a drafting detail attorneys should note. This comprehensive scope prevents any exclusivity-gap strategy by the generic filer.
Freedom-to-Operate-Analyse (FTO)
This case highlights critical IP risks in pharmaceutical extended-release formulations. Choose your next step:
📋 Die Auswirkungen dieses Falls verstehen
Informieren Sie sich über die spezifischen Risiken und Auswirkungen dieses Rechtsstreits.
- Alle 4 Patente in diesem Technologiebereich anzeigen
- See which companies are most active in OAB drug patents
- Understand claim scope of ER patents
🔍 Das Risiko meines Produkts überprüfen
Run a comprehensive FTO analysis for your own generic formulation or compound.
- Geben Sie Ihre Produktbeschreibung oder technischen Merkmale ein.
- KI identifiziert potenziell blockierende Patente
- Erhalten Sie einen umsetzbaren Risikobewertungsbericht
Hochrisikogebiet
Mirabegron extended-release formulations
4 Patents
In this formulation family
Design-Around-Optionen
Für einige Ansprüche verfügbar
✅ Wichtigste Erkenntnisse
Multi-patent Hatch-Waxman assertion strategies create compounding settlement pressure on ANDA challengers.
Verwandte Rechtsprechung suchen →Consent judgments should expressly extend injunctions through all patent term extensions, adjustments, and regulatory exclusivities.
Präzedenzfälle erkunden →Häufig gestellte Fragen
The case involved four patents — referred to as the ‘780, ‘451, ‘409, and ‘189 patents — including U.S. Patent No. US11707451B2, covering Mirabegron extended-release tablet formulations in 25 mg and 50 mg dosages.
Lupin admitted that all four asserted patents are valid and enforceable and that at least one claim of each patent is infringed by its ANDA products, resulting in a permanent injunction through patent expiration.
The consolidated consent judgments across multiple Lupin-related actions effectively delay generic Mirabegron entry until expiration of the full patent family, including all patent term extensions and regulatory exclusivities.
Sind Sie bereit, Ihre IP-Strategie im Pharmabereich zu stärken?
Schließen Sie sich den über 18.000 Fachleuten aus dem Bereich des geistigen Eigentums an, die PatSnap Eureka nutzen, um mit KI-gestützter Präzision Recherchen zum Stand der Technik durchzuführen, Patentanmeldungen zu erstellen und Wettbewerbslandschaften zu analysieren.
Referenzen
- United States District Court for the District of Delaware — Civil Action No. 1:23-cv-00819 (PACER)
- U.S. Patent and Trademark Office — U.S. Patent No. US11707451B2
- Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act)
- FDA — ANDA Resources
- PatSnap — Pharmaceutical IP Solutions
Dieser Artikel dient ausschließlich zu Informationszwecken und stellt keine Rechtsberatung dar. Alle Angaben zu den Fällen stammen aus öffentlich zugänglichen Gerichtsakten. Informationen zu den Funktionen der Plattform finden Sie auf PatSnap.